Skip to main content
. Author manuscript; available in PMC: 2024 Feb 1.
Published in final edited form as: Obstet Gynecol. 2023 Jan 4;141(2):341–353. doi: 10.1097/AOG.0000000000005044

Table 2.

Analysis of live birth outcomes after cancer diagnosis and fertility-sparing surgery by cancer type

Sociodemographic and clinical characteristics Cervical Cancer (n=639) Ovarian Cancer (n=594)
Live Birth (n=110) No Live Birth (n=529) P Value Live Birth (n=115) No Live Birth (n=479) P Value
Age (years), n (%) <0.01 <0.01
 18–35 99 (21.9) 354 (78.1) 109 (24.4) 338 (75.6)
 36–45 11 (5.9) 175 (94.1) * *
Diagnosis year, n (%) <0.01 <0.01
 2000–2005 63 (23.3) 207 (76.7) 75 (29.4) 180 (70.6)
 2006–2012 47 (12.7) 322 (87.3) 40 (11.8) 299 (88.2)
SES, n (%) 0.42 0.05
 Lowest 14 (12.3) 100 (87.7) 22 (28.9) 54 (71.1)
 Lower-middle 18 (16.4) 92 (83.6) 29 (23.8) 93 (76.2)
 Middle 22 (18.5) 97 (81.5) 19 (13.7) 120 (86.3)
 Upper-middle 33 (21.2) 123 (78.8) 21 (16.4) 107 (83.6)
 Highest 23 (16.4) 117 (83.6) 24 (18.6) 105 (81.4)
Charlson comorbidity score, n (%) <0.01 0.35
 Score=0 62 (13.7) 389 (86.3) 105 (20.2) 414 (79.8)
 Score≥1 * * * *
 Unknown 44 (28.8) 109 (71.2) * *
Insurance, n (%) 0.90 0.88
 Public 17 (16.3) 87 (83.7) 16 (20.8) 61 (79.2)
 Private 72 (16.8) 356 (83.2) 79 (19.0) 337 (81.0)
 Uninsured/self-pay * * * *
 Other/unknown 17 (20.0) 68 (80.0) 14 (18.2) 63 (81.8)
Marital status, n (%) 0.02 0.40
 Single 41 (14.1) 250 (85.9) 53 (17.1) 257 (82.9)
 Married 57 (22.4) 198 (77.6) 51 (22.1) 180 (77.9)
 Other * * * *
 Unknown * * * *
Race or ethnicity, n (%) 0.03 0.23
 American Indian * * 0 (0.0) *
 Asian or Pacific Islander * * 29 (22.5) 100 (77.5)
 Hispanic 37 (21.0) 139 (79.0) 45 (22.8) 152 (77.2)
 Non-Hispanic Black * * * *
 Non-Hispanic White 54 (16.5) 273 (83.5) 33 (14.6) 193 (85.4)
 None of the above * 13 (65.0) * *
Rurality, n (%) 0.46 0.11
 Rural 12 (20.7) 46 (79.3) * 37 (90.2)
 Urban 98 (16.9) 483 (83.1) 111 (20.1) 442 (79.9)
Parity, n (%) <0.01 0.01
 0 71 (14.8) 409 (85.2) 100 (20.2) 396 (79.8)
 1 24 (34.3) 46 (65.7) 13 (27.7) 34 (72.3)
 ≥2 15 (16.9) 74 (83.1) * *
Cancer stage, n (%) 0.03 0.37
 1A 96 (18.8) 414 (81.2) 91 (20.2) 360 (79.8)
 1B 14 (10.9) 115 (89.1) NA NA
 1C NA NA 24 (16.8) 119 (83.2)
Histology, n (%) 0.97 0.01
 Adenocarcinoma 29 (17.6) 136 (82.4) NA NA
 Adenosquamous carcinoma * * NA NA
 Squamous carcinoma 74 (17.1) 358 (82.9) NA NA
 Endometrioid adenocarcinoma NA NA NA NA
 Germ cell NA NA 54 (26.1) 153 (73.9)
 Sex cord stromal NA NA * *
 Epithelial NA NA 53 (15.4) 291 (84.6)
 None of the above * * 0 (0.0) 0 (0.0)
Chemotherapy, n (%) 1.00 0.97
 Yes 0 (0.0) * 38 (19.5) 157 (80.5)
 No 110 (17.4) 522 (82.6) 75 (19.2) 315 (80.8)
 Unknown 0 (0.0) * * *
Hormonal therapy, n (%) 0.83 0.48
 Yes 0 (0.0) * * *
 No 110 (17.2) 528 (82.8) 114 (19.3) 477 (80.7)
 Unknown 0 (0.0) * 0 (0.0) 0 (0.0)

SES, socioeconomic status; NA, not applicable.

Live birth was defined as a live birth that had been conceived 3 months after the cancer diagnosis and fertility-sparing surgery. The three births that occurred among patients with a history of endometrial cancer are not presented because of the low number of results to protect the confidentiality of individuals represented in these data. Those who had prior radiation or were diagnosed after 2012 were excluded from analysis, due to contraindication to attempting a live birth and lack of data, respectively.

*

Values are not shown to protect the confidentiality of the individuals summarized in the data.

”Other” marital status included separated, divorced, widowed, unmarried, or in a domestic partnership.

Specific histology codes are listed in Appendix 2 (http://links.lww.com/xxx).